Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer is facing significant ... business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

The stock price dropped after the Q2 earnings release despite strong performance ... fair given that Pfizer's YoY and FWD revenue growth is deeply negative. Looking at peer analysis of valuation ...

Pfizer Inc. (NYSE:PFE), one of the ... According to InvestingPro analysis, the stock currently appears undervalued compared to its Fair Value estimate, presenting a potential opportunity for ...

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

Our detailed analysis of Pfizer’s upside post-inflation shock ... It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE ... and the cancellation of unvested performance stock units unless they publicly support the current CEO.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...